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Abstract
The desmosomal cadherin, desmoglein 2 (Dsg2), is deregulated in a variety
of human cancers including those of the skin. When ectopically expressed in the
epidermis of transgenic mice, Dsg2 activates multiple mitogenic signaling pathways
and increases susceptibility to tumorigenesis. However, the molecular mechanism
responsible for Dsg2-mediated cellular signaling is poorly understood. Here we show
overexpression as well as co-localization of Dsg2 and EGFR in cutaneous SCCs in
vivo. Using HaCaT keratinocytes, knockdown of Dsg2 decreases EGFR expression
and abrogates the activation of EGFR, c-Src and Stat3, but not Erk1/2 or Akt, in
response to EGF ligand stimulation. To determine whether Dsg2 mediates signaling
through lipid microdomains, sucrose density fractionation illustrated that Dsg2 is
recruited to and displaces Cav1, EGFR and c-Src from light density lipid raft fractions.
STED imaging confirmed that the presence of Dsg2 disperses Cav1 from the cellcell borders. Perturbation of lipid rafts with the cholesterol-chelating agent MβCD
also shifts Cav1, c-Src and EGFR out of the rafts and activates signaling pathways.
Functionally, overexpression of Dsg2 in human SCC A431 cells enhances EGFR
activation and increases cell proliferation and migration through a c-Src and EGFR
dependent manner. In summary, our data suggest that Dsg2 stimulates cell growth
and migration by positively regulating EGFR level and signaling through a c-Src and
Cav1-dependent mechanism using lipid rafts as signal modulatory platforms.

INTRODUCTION

adenoviruses that are involved in respiratory and urinary
tract infections [4]; and Dsg2 has been identified as a
regulator of β-amyloid protein processing in Alzheimer’s
disease [5]. Ectodomain shedding of Dsg2 disrupts
intercellular adhesion and promotes cell proliferation to
promote wound repair in ulcerative colitis [6]. In mice,
Dsg2 gene knockout results in defects in blastocyst
proliferation and embryonic lethality [7]. Conversely,
expression of Dsg2 in the superficial epidermis of
transgenic mice enhances cell proliferation and increases
susceptibility to chemical-induced skin carcinogenesis [8].
Dsg2 is markedly increased in skin malignancies
including basal and squamous cell carcinoma (BCC and

Desmogleins are transmembrane glycoproteins
of the adhesion structures desmosomes. Of particular
interest to this study is desmoglein 2 (Dsg2), which is
expressed in the basal epidermis, intestinal epithelia,
cardiac tissue, and hair follicles [1, 2]. The role of Dsg2
and related desmogleins in desmosome assembly and
adhesion is well known, but its role beyond cellular
adhesion is an emerging focus of research. In humans,
mutations in the Dsg2 gene are the underlying cause of the
sudden death condition arrhythmogenic right ventricular
cardiomyopathy [3]; Dsg2 serves as a receptor for
www.impactjournals.com/oncotarget
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SCC) [1, 9-12]. Altered Dsg2 expression also occurs in
prostate and colon cancers, suggesting a role for Dsg2
in oncogenesis in a variety of epithelial tissues [13-16].
Loss of Dsg2 in colonic epithelial carcinoma cells results
in decreased proliferation and suppresses xenograft tumor
growth in mice [17]. However, in diffuse-type gastric
cancers, decreased expression of Dsg2 is associated
with poor prognosis suggesting that Dsg2 may have
dual roles as an oncogene and a tumor-suppressor gene
[18]. The signaling pathways through which Dsg2 exerts
its observed oncogenic effects remain to be elucidated.
We previously showed that Dsg2 enhances activation of
growth and survival pathways, including PI3K/Akt, MEKErk1/2, JAK/Stat3 and NF-κB [8] and alters a number of
genes important in epithelial dysplasia [19]. Interestingly,
these signaling pathways are downstream of the epidermal
growth factor receptor (EGFR) and activation with EGF
increases association of EGFR binding to Dsg2 [20].
Furthermore, Dsg2 upregulates Hedgehog signaling and
in response to chemical carcinogens, enhances BCC and
SCC tumor development [21].
The mechanism by which Dsg2 modulates signaling
may involve its interaction with caveolin-1 (Cav1), an
integral membrane protein of caveolar lipid rafts [2225]. Cav1, through its cytosolic caveolin scaffolding
domain, can interact with and sequester a number of
different signaling molecules including EGFR [26]. Both
tumor growth and anchorage-independent cell survival
are negatively impacted by Cav1 overexpression [27,
28]. EGFR-stimulated phosphorylation of tyrosine 14 of
Cav1 has been shown to promote caveolae formation in
a c-Src-dependent manner, which in turn promotes EGFR
sequestration and inactivation [29, 30]. Active signaling
through EGFR requires disassociation from caveolae;
given Dsg2’s association with Cav1 and the established
interactions between Dsg2 and EGFR, we examined the
potential role of Dsg2-mediated modulation of EGFR
signaling [14, 17, 22, 31-35].
Herein we report that Dsg2 and EGFR expression
is upregulated and colocalizes in human SCCs.
Knockdown of Dsg2 reduces EGFR level and activation.
Furthermore, Dsg2 mobilizes Cav1, EGFR, and c-Src
lipid raft localization, altering cell signaling. Additionally,
overexpression of Dsg2 enhances proliferation and
migration in cancer cells. Taken together, these results
reveal a distinct signal-regulating role for Dsg2 beyond its
function in cell-cell adhesion.

in multiple malignancies, including SCCs. Furthermore,
we demonstrated that Dsg2 activates the MAPK, PI3K/
Akt and JAK/Stat3 pathways [8]. The mechanism by
which Dsg2 activates mitogenic signaling is not fully
determined but has been speculated to be through EGFR.
To determine whether the interaction between Dsg2
and EGFR is relevant to skin cancer development, SCC
tissues were immunostained for Dsg2 and EGFR, showing
not only upregulation, but also co-localization, of Dsg2
and EGFR in these tissues in vivo (Figure 1). Next, to
determine whether Dsg2 modulates EGFR, we generated
stable HaCaT (spontaneously transformed immortalized
keratinocyte) cell lines expressing a short hairpin RNA
(shRNA) directed against human Dsg2 (shDsg2) and
Green Fluorescent Protein (shGFP) as a negative control.
Immunofluorescence (Figure 2A) and immunoblotting
(Figure 2B) show reduced expression of Dsg2 protein in
HaCaT-shDsg2 knockdown (KD) compared to HaCaTshGFP. Quantification of the Western blots demonstrate
that the shRNA reduced Dsg2 by ~70% and EGFR by
~40% in HaCaT-shDsg2 as compared to control cells
(Figure 2B). Collectively, our data demonstrate that
knockdown of Dsg2 reduced EGFR level in HaCaT cells.
Changes in Dsg2 did not affect the expression of other
desmosome-associated proteins in HaCaT cells except
desmocollin 2 (Dsc2) (Figure 2C). This result contrasts
colon cancer cells [17], where KD of Dsg2 in malignant
colonic epithelial cells led to a concomitant increase in
Dsc2. The mechanism by which Dsg2/Dsc2 modulates
the expression of each other in keratinocytes likely differs
from that of simple colon epithelial cells.
Next we sought to determine the effect of Dsg2 on
EGFR activation. In response to EGF ligand stimulation,
control HaCaT-shGFP cells showed a robust increase
in phosphorylated EGFR (P-EGFR, Tyr1173), which
was dramatically abrogated in Dsg2 KD cells (Figure
3A). Phosphorylation of EGFR at Tyr1173 is critical for
downstream MAP kinase signaling [36]. To assess the
effect of Dsg2 on the MEK/Erk1/2, PI3K/Akt and JAK/
Stat3 signaling pathways, HaCaT-shGFP and -shDsg2
cells were stimulated with EGF and immunoblotted for
Phospho-Erk1/2, -Akt, and -Stat3. In response to EGF,
activation of EGFR resulted in Erk1/2, Akt and Stat3
phosphorylation (Figure 3B). Reduced expression of Dsg2
did not affect either Erk1/2 or Akt phosphorylation, but
dramatically reduced Stat3 phosphorylation (Figure 3B).
Treatment with the MEK inhibitor PD98059 or the PI3K
inhibitor Wortmannin blocked Erk1/2 and Akt signaling,
respectively (Figure 3B). Since EGFR activation is
upstream of Erk1/2 and Akt, PD98059 and Wortmannin
did not affect EGFR phosphorylation in response to EGF
ligand stimulation. Furthermore, Wortmannin had no
effect on Stat3 phosphorylation while PD98059 treatment
slightly increased Stat3 activation, likely due to blocking
the inhibitory Erk1/2-mediated phosphorylation of Stat3
(Ser727) [37].

RESULTS
Dsg2 enhances EGFR level and activation
Dsg2 and EGFR have been shown to enhance
epithelial cell growth and survival and are overexpressed
www.impactjournals.com/oncotarget
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In spite of reduced phosphorylation of EGFR at
tyrosine 1173, Erk1/2 was still activated in response
to EGF stimulation. To further assess whether Dsg2
modulates unique EGFR phosphorylation sites, HaCaTshGFP and -shDsg2 cells were treated with EGF for
5 to 60 min, and protein lysates were immunblotted
for P-EGFR at Tyr1173, Tyr1045 and Tyr845 (Figure
3C). These phosphorylation sites are associated with
downstream MAPK activation (Tyr1173), c-Cbl-mediated

receptor degradation (Tyr1045), and c-Src activation
(Tyr845) [38-40]. The results showed that Dsg2 KD
reduced EGFR phosphorylation at Tyr1173 and Tyr845 for
all time points. Interestingly, phosphorylation at Tyr1045
was immediate—within 5 min after EGF stimulation—and
Dsg2 KD only slightly attenuated the signal, suggesting
that ubiquitin-mediated receptor degradation is largely
unaffected by loss of Dsg2. These results demonstrate that
Dsg2 had a distinct role in modulating the phosphorylation

Figure 1: Co-localization of Dsg2 and EGFR in squamous cell carcinomas. Two representative SCCs were co-immunostained
for Dsg2 (green) and EGFR (red). DAPI to label nuclear DNA (blue). Scale bar = 50 µm.
www.impactjournals.com/oncotarget
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of EGFR at Tyr1173 and Tyr845. Furthermore, the MEK/
Erk1/2 pathway was activated either independent of EGFR
or through a phosphorylation site, different from Tyr1173

and Tyr845 that was not assessed.
In addition to HaCaT cells, we also generated A431
epidermoid cancer cells expressing the shGFP and shDsg2

Figure 2: Knockdown of Dsg2 reduces EGFR. A. HaCaT keratinocytes were stably transfected with shRNA to GFP (shGFP)

or Dsg2 (shDsg2) and selected in puromycin. Cells were plated on glass slides and processed for immunofluorescence for Dsg2 (green)
and EGFR (red). Blue DAPI counterstain for nuclei. Scale bar = 100 µm. B. Total lysates from HaCaT-shGFP and -shDsg2 cells were
immunoblotted for Dsg2, EGFR and GAPDH for equal loading. Densitometry was performed and histogram bars represent the relative
amount of Dsg2 normalized GAPDH. Data are expressed as average value ± s.e.m. of at least 3 independent experiments. Dsg2 (shGFP,
1.00±0.12; shDsg2, 0.25±0.06); EGFR (shGFP, 1.00±0.20; shDsg2, 0.58±0.09); **p < 0.01; ***p < 0.001; t-test. C. HaCaT-shGFP and
-shDsg2 cells were immunoblotted for Dsg1-4, desmocollin 2 (Dsc2), desmoplakin (DP), plakoglobin (PG), plakophilin 1-3 (PkP1-3),
E-cadherin (E-cad), β-catenin (β-cat) and GAPDH. Blotting for β-actin and GAPDP showed equal loading. Densitometry represents the
ratio of Dsc2/GAPDH expressed as average value ± standard of the mean. N = 3. Dsc2 (shGFP, 0.57±0.03; shDsg2, 0.22±0.06); *p < 0.05;
t-test.
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Figure 3: Dsg2 modulates EGFR and Stat3 activation. A. HaCaT-shGFP and -shDsg2 cells were serum-starved and then stimulated

with EGF (10 nM). Total proteins were immunoblotted for active P-EGFR (Tyr1173), EGFR, and GAPDH as loading control. Densitometry
was performed, and histogram bars represent the relative amount of Dsg2 and EGFR normalized to GAPDH in untreated cells, and the ratio
of P-EGFR (Tyr 1173) to total EGFR after 1 hr of stimulation was quantified and plotted. Data are expressed as average value ± s.e.m of at
least 3 independent experiments. Dsg2 (shGFP, 1.00±0.12; shDsg2, 0.25±0.06); EGFR (shGFP, 1.00±0.20; shDsg2, 0.58±0.09); (shGFP,
1.00±0.04; shGFP+EGF, 4.39±0.08; shDsg2, 0.22±0.04; shDsg2+EGF, 1.12±0.11); **p < 0.01; ***p < 0.001; t-test. B. HaCaT-shGFP
and -shDsg2 cells were incubated with PD098059 (50 µM) or Wortmannin (100 nM) for 1 h prior to treatment with EGF (10 nM) for 1
h. Cell lysate was subjected to Western blotting analysis for P-EGFR (Tyr1173), EGFR, P-Erk (Thr202/Tyr204), P-Akt (Thr308), P-Stat3
(Tyr705), and GAPDH for loading control. Results shown are representative of three independent experiments. C. HaCaT-shGFP and
-shDsg2 cells were treated with EGF (10 nM) for 5, 10, 15, 30 and 60 min. Cells were lysed and total proteins immunoblotted for Dsg2,
EGFR, P-EGFR (Tyr1173, Tyr1045 and Tyr845), and GAPDH as loading control.
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Figure 4: Knockdown of Dsg2 in A431 SCC cells reduces EGFR phosphorylation. A. A431 cells were stably transfected with

shRNA to GFP (shGFP) or Dsg2 (shDsg2) and selected in puromycin. Total cell lysates were immunoblotted for Dsg2, EGFR and P-EGR
(Tyr1173). Blotting for GAPDH showed equal loading. Densitometry was performed and bars represent the ratio of Dsg2 to GAPDH, total
EGFR to GAPDH and P-EGFR to total EGFR. Data are expressed as average value ± standard error of the mean of three independent
experiments. n.s.p > 0.05; *p < 0.05; t-test. B. Immunoblotting of A431-shGFP and -shDsg2 cells for Dsg2 and Dsc2 with GAPDH as loading
control. .N = 3.
www.impactjournals.com/oncotarget
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constructs. A431-shDsg2 cells showed a slight, but not
statistically significant decrease in total EGFR (Figure
4A). We attribute this to the substantially high expression
of endogenous EGFR in A431 cells [41]. Similar to
previous reports, we observed high levels of activated

EGFR in control A431 cells [42]. While total EGFR
was relatively unchanged, P-EGFR was significantly
reduced in A431-shDsg2 cells suggesting that, similar to
HaCaT cells, reduced Dsg2 expression suppresses EGFR
phosphorylation and activation (Figure 4A). Additionally,

Figure 5: Dsg2 modulates EGFR activation through a c-Src-dependent pathway. A. HaCaT-shGFP and -shDsg2 cells were
stimulated with EGF (10 nM) and proteins immunoblotted for P-c-Src (Tyr416), total c-Src and GAPDH as loading control. Bar graphs
show relative ratio of total c-Src/GAPDH (left) and P-c-Src (Tyr416)/total c-Src (right). Data are expressed as average value ± s.e.m.
of three independent experiments. c-Src (shGFP, 1.00±0.16; shDsg2, 1.00±0.30); P-c-Src (shGFP, 1.00±0.08; shGFP+EGF, 0.88±0.15);
P-c-Src (shDsg2, 0.57±0.16; shDsg2+EGF, 0.40±0.03); Not significant n.s.p > 0.05; *p < 0.05; ***p < 0.001; t-test. B. HaCaT cells were
treated with the c-Src inhibitor PP2 (30 µM) for 1 h and then stimulated with EGF (10 nM) for 1 h prior to cell lysis. Total cellular proteins
were subjected to immunoblotting for P-EGFR (Tyr1173), EGFR, P-Stat3 (Tyr705), Stat3, P-c-Src (Tyr416), c-Src and GAPDH. Data are
expressed as average value ± s.e.m. of six independent experiments. P-EGFR (shGFP, 1.00±0; shGFP+EGF, 5.09±0.49; shGFP+EGF+PP2,
2.74±0.26); P-c-Src (shGFP, 1.00±0; shGFP+EGF, 1.62±0.22; shGFP+EGF+PP2, 0.67±0.20); P-Stat3 (shGFP, 1.00±0; shGFP+EGF,
3.74±1.85; shGFP+EGF+PP2, 7.75±1.99); Not significant n.s.p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001; t-test.
www.impactjournals.com/oncotarget
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similar to the HaCaT-shDsg2 cells, a decrease in Dsc2
expression was observed in A431-shDsg2 cells, further
illustrating a lineage-specific modulation of Dsg2/
Dsc2 expression (Figure 4B). Due to the high level of
endogenous EGFR and P-EGFR in A431 cells, and
that the A431 cells would rapidly select against loss of
Dsg2, we chose to use HaCaT cells for further mitogenic
signaling analysis.

assessed the levels of total and active phosphorylated
c-Src. Consistent with previous findings, we observed
constitutively active P-c-Src (Tyr416) in control HaCaTshGFP cells (Figure 5A) [46]. Dsg2 did not affect
total c-Src; however, activated P-c-Src (Tyr416) was
dramatically reduced in the Dsg2 KD cells (Figure
5A). Inhibition of c-Src with the inhibitor PP2 partially
abrogated phosphorylation of EGFR in response to
EGF ligand in HaCaT cells (Figure 5B), confirming
previous findings that c-Src acts both upstream as well
as downstream of EGFR [47]. Thus, the Dsg2-dependent
EGFR activation may be modulated, in part, by c-Src.
Interestingly, inhibition of c-Src slightly increased Stat3
activation (Figure 5B). Reciprocal regulation of c-Src and
Stat3 activation has been observed in non-small cell lung
cancer cell lines (NSCLC) or tumor xenografts treated
with anti-c-Src modalities and in NSCLC human patients
[48].

Dsg2 modulates c-Src phosphorylation and
activity
The proto-oncogene c-Src is a known regulator and
effector of EGFR and Stat3 activation, a transcription
factor with oncogenic potential and anti-apoptotic
activities [43-45]. In order to determine whether the
effect of Dsg2 on EGFR is mediated through c-Src, we

Figure 6: EGFR and c-Src signaling is mediated, in part, through lipid rafts. HaCaT-shGFP and -shDsg2 cells were lysed in

1% TX-100 TNE lysis buffer and proteins separated by ultracentrifugation (38,000 RPM) over a sucrose gradient (5, 35, and 45%). Twelve
1 mL fractions were collected from the top and prepared for immunoblot analysis using antibodies specific for Dsg2, Cav1, flotillin 1 (Flo1),
c-Src, EGFR and Actin. Light-density lipid raft fractions: 4 and 5. Bands were quantitated and bar graphs show relative ratio of fractions
4 and 5 to all fractions. Loss of Dsg2 increases EGFR, c-Src, and Cav1 in the lipid raft fractions. EGFR (shGFP, 1.13±0.21; shDsg2,
3.17±0.41); c-Src (shGFP, 7.46±2.68; shDsg2, 19.11±3.08); Cav1 (shGFP, 3.17±0.88; shDsg2, 6.70±0.54); *p < 0.05; t-test.
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Dsg2 alters composition of lipid rafts and activates
c-Src and EGFR

Dsg2 and caveolin 1 (Cav1), a known negative regulator
of the activities of c-Src and EGFR [22, 49, 50]. However,
it is not known whether Dsg2 modulates EGFR and c-Src
activity through lipid rafts. Down-regulation of Dsg2 in

Our previous work identified an interaction between

Figure 7: EGFR signaling is mediated through Cav1 and lipid rafts. A. HaCaT-shDsg2 and -shGFP cells were treated with

1% MβCD for 1 h and total protein lysates were immunoblotted for P-EGFR (Tyr1173), EGFR, P-c-Src (Tyr416), c-Src and GAPDH.
Bar graphs show relative ratio of P-EGFR to total EGFR and P-c-Src to total c-Src. Data are expressed as average value ± s.e.m. of three
independent experiments. P-EGFR (shGFP, 1.00±0.16; shGFP+MβCD, 2.64±0.12; shDsg2, 0.04±0.01; shDsg2+MβCD, 1.07±0.04); P-cSrc (shGFP, 1.00±0.20; shGFP+MβCD, 1.10±0.09; shDsg2, 0.17±0.02; shDsg2+MβCD, 0.55±0.04); n.s.p > 0.05; * p < 0.05; t-test. B.
HaCaT cells were incubated with the biotinylated AP ([(biotin)-RQPKIWFPNRRKPWKK-(OH)]; 5 μM) or the Cav-1 consensus binding
peptide conjugated to AP (AP-Cav1; [(biotin)-RQPKIWFPNRRKPWKKDGIWKASFTTFTVTKYWFYR-(OH)]; 5 μM) for 1 h prior to
stimulation with 10 ng/mL EGF for 1 h. Total cell lysates were immunoblotted for P-EGFR (Tyr1173) and GAPDH (for equal loading). Bar
graph shows quantitated values from 3 independent experiments.
www.impactjournals.com/oncotarget
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HaCaT keratinocytes did not alter total Cav1 level (not
shown). To determine whether Dsg2 modulates Cav1
membrane raft localization, we relied on the fact that
caveolae are buoyant Triton X-100 insoluble membrane
fractions and can be isolated through sucrose density
gradient centrifugation [22]. In control cells, we detected
Cav1, flotillin 1, c-Src and, to a lesser level, EGFR in the
light density raft fractions 4 and 5 that are demarcated as
containing constituents of caveolae, per the immunoblot
for Cav1 (Figure 6). Reduced expression of Dsg2 shifted a
higher portion of total Cav1, c-Src and EGFR into the raft
fractions. In contrast, lipid raft localization of flotillin-1, a
scaffolding protein associated with planar-type lipid rafts,
was not affected by Dsg2 expression. Cav1 negatively
regulates cellular signaling by sequestering signaling
molecules in their inactive state within the caveolae [25].
Together these data suggest that Dsg2 enhances activation
of c-Src and EGFR by disrupting their association with
lipid rafts.
Lipid raft-mediated internalization potentially serves
as a mechanism for EGFR degradation, independent from
clathrin-dependent endocytosis and membrane recycling.
Given that lipid rafts can repress extended EGFR
activation and loss of Dsg2 attenuates receptor activation,
disruption of either the EGFR-lipid raft or lipid raft-Dsg2
interactions should promote receptor activation. Methylβ-cyclodextrin (MβCD) perturbs lipid raft structure and
releases its constituents by chelating cholesterol away
from the rafts. Treatment of HaCaT-shGFP and HaCaTshDsg2 cells with MβCD did not alter total level of c-Src
or EGFR, but increased their activation (Figure 7A).
Interestingly, KD of Dsg2 decreased the activation of
P-c-Src and P-EGFR in response to MβCD, corroborating
with the observed decrease in total EGFR expression in
HaCaT-shDsg2 cells. To further demonstrate that EGFR
activation is mediated through Cav1 and caveolae,
we utilized a fusion of the cell permeable Drosophila
Antennapedia homeodomain and the Cav1 scaffolding
domain (Cav1-AP) or a non-specific peptide as a control
(AP). This Cav1-AP peptide would disrupt the interaction
between Cav1 and its binding partners including, Dsg2
and EGFR [20]. In unstimulated HaCaT cells, AP or
AP-Cav1 peptides did not have an effect on EGFR
phosphorylation (Figure 7B). EGFR phosphorylation
increased in response to EGF ligand stimulation and while
the AP control peptide impaired EGFR phosphorylation,
AP-Cav1 significantly reduced the phosphorylation level
(Figure 7B). We previously showed that AP-Cav1, but not
AP, slightly reduced Dsg2 level in lipid raft fractions [22].
Interestingly, AP-Cav1 had no effect on the activation
of EGFR in HaCaT-shDsg2 cells (not shown), which
already had abrogated ligand-induced EGFR activation,
further demonstrating that connection between receptor
activation and Dsg2. Both MβCD and AP-Cav1 treatment
in Dsg2-depleted cells illustrate that EGFR activation in
keratinocytes can be dependent upon the ability of Dsg2
www.impactjournals.com/oncotarget

to modulate receptor association with caveolae.
To more precisely illustrate that expression of
Dsg2 disrupts Cav1 membrane localization, we utilized
stimulated emission depletion (STED) super-resolution
microscopy [51]. We relied on the fact that the knockdown
of Dsg2 was not complete in the HaCaT-shDsg2 cells,
with some patches of HaCaTs expressing Dsg2 and
permitting the visualization of Cav1 in both the presence
and absence of Dsg2 (Figure 8A). Confocal images of
Dsg2 (red), Cav1 (green) and merged demonstrate the
presence of Dsg2 and Cav1 at cell-cell contacts in both
Dsg2-expressing and Dsg2-KD HaCaTs (Figure 8A).
Utilizing STED at an intersection of three cell-cell borders
for enhanced analysis, Cav1 signal was concentrated
at the cell-cell border between cells lacking Dsg2 but
became dispersed and scattered in the presence of Dsg2
(Figure 8B). This suggests that the physical presence of
Dsg2 disrupted well-defined Cav1 localization to the cell
membrane. By calculating the intensity of Dsg2 and Cav1
staining perpendicularly across both Dsg2-expressing
and non-expressing cell-cell borders, it was apparent that
higher Dsg2 expression redistributed Cav1 intracellularly
(Figure 8B). This disruption of Cav1 by Dsg2 was further
confirmed by calculating the relative fluorescent intensity
of Cav1 at cell contacts in Dsg2-overexpressing and
Dsg2-KD HaCaTs from confocal images (Figure 8C).
HaCaTs without cell-cell Dsg2 staining had a distinct
peak of Cav1 centered in and immediately around the cell
membrane whereas Dsg2-expressing cells generally had
Cav1 distributed further into the cytosol. These results
begin to suggest that Dsg2 may promote Cav1/caveolae
internalization; indeed, the cytosolic shift of Cav1 was
even apparent in Dsg2-expressing cells that bordered cells
without Dsg2 (data not shown). We observed modulated
levels of Cav1 in the perimembrane region, suggesting
an important dynamic between Dsg2 and membranepresentation of Cav1.

Dsg2 enhances SCC cell proliferation and
migration through EGFR and c-Src
To further study the ability of Dsg2 to modulate
the activation of EGFR and its relevance to cancer, we
generated stable A431 SCC cells expressing a GFPlabeled Dsg2 (upper band; Figure 9A). We note that the
endogenous Dsg2 and the ectopically expressed Dsg2-GFP
localized similarly in light density fractions confirming
that Dsg2-GFP did not affect endogenous Dsg2 lipid
raft association (not shown). We opted to use A431 for
additional study, as it is a well-characterized keratinocytederived tumorigenic cell line amenable to both Dsg2
overexpression and phenotypic analysis. Furthermore,
unlike HaCaTs, A431 cells can be used unstimulated in the
transwell migration assay. Interestingly, overexpression of
Dsg2-GFP did not significantly alter the level of EGFR
37545
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Figure 8: Dsg2 displaces Cav1 from cell-cell borders. A. Immunofluorescent staining of HaCaT-shGFP and HaCaT-shDsg2 cells

for Cav1 (green), Dsg2 (red) and visualized by confocal microscopy showing more defined Cav1 staining in the absence of Dsg2 (arrow).
B. Staining was visualized and imaged by STED super-resolution microscopy. The average intensity of Cav1 and Dsg2 staining was
calculated across the cell-cell border of the boxed areas of the merged STED image. Briefly, measurements of the fluorescent intensity for
both Cav1 and Dsg2 was obtained in ImageJ with a line 6.25 μm long centered on the Cav1 staining (dashed vertical line) and originating
from left to right (dashed arrow) perpendicularly across the width of the cell-cell border. Multiple line measurements were taken along the
length of the distinct cell-cell borders and intensity values averaged to produce both the Dsg2-absent (top graph) and Dsg2-positive cell
border staining of Cav1 and Dsg2. Scale bars = 5 μm. C. Average fluorescent intensity quantitated from Dsg2 (red) and Dsg2 KD (blue)
cell-cell borders (n = 18 each). *p < 0.05, **p < 0.01***p < 0.001; t-test.
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Figure 9: Dsg2-mediated SCC cell growth and migration is dependent on EGFR and c-Src. A. A431 cells were transduced

with retroviruses encoding for GFP-labeled Dsg2. Total protein lysates from A431 and A431-Dsg2/GFP cells were immunoblotted for Dsg2,
pEGFR, and EGFR. Actin served as loading control. P-EGFR (A431, 100±26.5; A431-Dsg2/GFP, 413±74.5) *p < 0.05; ***p < 0.001;
t-test. The effect of Dsg2 on cell proliferation and migration was assessed. B. A431 and A431-Dsg2/GFP cells were plated at low density for
6 days in the presence of Erlotinib, PP2 or both. Cells were trypsinized and counted (n = 14). A431, 100.0±6.6; A431+Erlotinib, 11.9±1.9;
A431+PP2, 67.4±3.0; A431+Erlobtinib+PP2, 4.1±0.7; A431-Dsg2/GFP, 165.7±16.8; A431-Dsg2/GFP+Erlotinib, 25.4±0.9; A431-Dsg2/
GFP+PP2, 123.4±4.5; A431-Dsg2/GFP+Erlobtinib+PP2, 10.7±0.8. C. For migration, cells treated with Erlotinib, PP2 or both in serum free
medium were plated in the top chamber and allowed to migrate through an uncoated Transwell membrane in response to serum-containing
medium in the lower chamber. The membranes were fixed and stained with methylene blue. Cells were counted and presented as percentages
of the control migration (n = 9). A431, 100.0±7.1; A431+Erlotinib, 53.7±4.6; A431+PP2, 33.1±5.9; A431+Erlotinib+PP2, 20.0±4.9; A431Dsg2/GFP, 233.8±37.6; A431-Dsg2/GFP+Erlotinib, 136.7±12.6; A431-Dsg2/GFP+PP2, 159.1±11.3; A431-Dsg2/GFP+Erlotinib+PP2,
31.9±6.4.
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but dramatically enhanced endogenous EGFR activation
(Figure 9A). Using these cell lines, we next sought to
determine the effect of Dsg2 on cancer cell growth and

migration and whether it is mediated through EGFR
and c-Src. Dsg2 enhanced SCC cell growth, which was
dramatically abrogated in the presence of the EGFR

Figure 10: Dsg2 enhances fibrosarcoma cell growth and migration. HT1080 cells were transduced with retroviruses encoding

for GFP-labeled Dsg2. A. Total protein lysates from HaCaT, HT1080 and HT1080-Dsg2/GFP cells were immunoblotted for desmosomal
proteins and actin as loading control. B. HT1080 and HT1080-Dsg2/GFP cell lysates were immunoblotted for Dsg2 and EGFR showing
enhanced EGFR level in response to Dsg2. C. Immunofluorescence of HT1080 and HT1080-Dsg2/GFP cells for Dsg2 and Cav1. Nuclei
stained blue with DAPI. Bar = 100 µm. D. Proliferation was assessed by cell counting. E. Migration potential was assessed by transwell
migration assay with HT1080 and HT1080-Dsg2/GFP cells. Migrated cells were counted and presented as percentages of the control.
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inhibitor Erlotinib (Figure 9B). The c-Src inhibitor PP2
only slightly reduced cell growth in response to Dsg2,
suggesting the prevalence of upstream EGFR activation
as a determinant of growth in these cells. However, the
combination of EGFR and c-Src inhibitors was synergistic
in reducing cell proliferation (Figure 9B). In addition to
modulating growth, Dsg2 also enhanced cell migration
through a transwell migration assay in response to Fetal
Bovine Serum (FBS) as a chemotactic factor (Figure
9C). The Dsg2-mediated increase in migration was
partially inhibited by Erlotinib and PP2 (Figure 9C)
further demonstrating the dependence of cell motility and
invasion upon EGFR and, to an extent, c-Src activation.
The combination of both inhibitors further abrogated the
migration of A431-Dsg2/GFP cells. In summary, these
results demonstrate that Dsg2 plays an active role in
modulating epithelial cell growth and migration through
EGFR and c-Src.

with the cholesterol-chelating agent MβCD shifts EGFR
and c-Src out of lipid raft fractions, resulting in enhanced
phosphorylation and activation of these two important
signaling components. Additionally, overexpression of
Dsg2 potently activates EGFR and enhances proliferation
and migration tumorigenic A431 and HT1080 cells. Taken
together, these data suggest a crosstalk between cell
adhesion and mitogenic signaling and that Dsg2 utilizes
lipid rafts as a platform to facilitate the activation of
EGFR and c-Src signaling.
EGFR phosphorylation at Tyr845 has been shown
to be c-Src-dependent, which, in turn, activates Stat3
transcriptional activity [39]. In addition to the role
of Tyr1173 phosphorylation in downstream MAPK
activation, SHP-1, a protein tyrosine phosphatase,
associates with activated EGFR at that residue and
attenuates receptor-mediated downstream signaling.
While it is not possible to rule out the effect of Dsg2
downregulation on other signal transduction pathways
that alter MAPK pathway activation, decreased EGFR
Tyr1173 phosphorylation has been shown to interfere with
the recruitment of SHP-1, but not SHC/Grb2 (mediators
of EGFR-induced MAPK activation), to active EGFR
[40]. Without the inhibitory phosphatase activity of SHP1, decreased EGFR activation mediated by loss of Dsg2
may not necessarily lead to significantly decreased MAPK
signaling. Indeed, the most profound effect observed on
downstream mitogenic signaling factors as a result of
decreased receptor activation from Dsg2 knockdown was
on the c-Src/Stat3 signaling axis.
Cell adhesion proteins are emerging as key players
in cancer progression and metastasis. We previously
showed that the desmosomal cadherin Dsg2 is highly
upregulated in several skin malignancies [9]. Furthermore,
overexpression of Dsg2 in the epidermis of transgenic
mice enhances EGFR level and activates mitogenic
signaling leading to epidermal hyperplasia and sensitivity
to tumor development [8]. EGFR is overexpressed and/
or activated in many human tumors including SCCs and
is often correlated to tumor aggressiveness [52]. Indeed,
we observed consistent co-localization of elevated Dsg2
and EGFR expression in human SCC samples (Figure
1) suggesting a functional interaction in the disease. In
cultured keratinocytes, overexpression of EGFR enhances
cell proliferation and survival [53, 54]. Overexpression
of Dsg2 induces potent EGFR expression and activation
that stimulates cell proliferation and migration (Figures
9 and 10). This effect is not desmosomal-dependent, as
the results were recapitulated in the fibrosarcoma-derived
HT1080 cell line that does not express desmosomes.
Interestingly, the HT1080 cell line expressed a small
amount of endogenous Dsg2 that, having been observed
previously, further suggests a desmosome-independent
role for Dsg2 [55]. Thus, our finding here that Dsg2 can
modulate EGFR activation is a critical link that connects
cell-cell adhesion to mitogenic signaling in skin cancer

Dsg2 enhances cell growth and migration
independent of desmosomes
HaCaT and A431 epithelial cells express
desmosomal proteins and establish desmosomal contacts.
Desmogleins, including Dsg2, are incorporated into
these cell-cell junctions, posing a challenge to delineate
whether the desmosome-bound or desmosome-free Dsg2
exerted the observed effects on growth and migration.
To assess the role of Dsg2 independent of desmosomes,
we employed the HT1080 fibrosarcoma-derived cells.
These cells express low levels of endogenous Dsg2, but
no significant amounts of other desmosomal proteins
(Figure 10A). Stable HT1080 cell lines were established
expressing Dsg2-GFP; Western blotting analysis
confirmed expression of the GFP-tagged Dsg2 protein
(upper band; Figure 10B). Immunofluorescence showed
both high membrane and cytoplasmic localization of
Dsg2 (Figure 10C). Furthermore, Dsg2 dramatically
enhanced EGFR levels (Figures 10B and C). Similar to
that observed in A431 SCC cells, ectopic overexpression
of Dsg2 enhanced HT1080 cell proliferation (Figure
10D) and migration (Figure 10E). These results support
the non-desmosome role of Dsg2 in cell proliferation and
migration, possibly through regulating EGFR.

DISCUSSION
In this study we have provided evidence that
reduced expression of the desmosomal junction protein
Dsg2 in epithelial keratinocytes reduces the activation
of both EGFR and c-Src, leading to a reduction in cell
proliferation. We also have demonstrated that Dsg2
displaces Cav1, the major integral membrane protein of
caveolae, as well as c-Src and EGFR, from lipid rafts
(Figure 6). In a similar manner, disruption of lipid rafts
www.impactjournals.com/oncotarget
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development. Dsg2 depletion in SK-CO15 colon cancer
cells also disrupts EGFR signaling [56]. However unlike
HaCaT keratinocytes, loss of Dsg2 does not alter the total
level of EGFR in SK-CO15 colon cancer cells. This may
be due to the constitutively high level of EGFR in cancers
cells such as A431 or SK-CO15.
In breast cancer cells, lipid rafts provide a platform
for the interaction of EGFR and c-Src, leading to activation
of cellular survival signaling [57]. Here, we observed that
reduced expression of Dsg2 decreases active P-c-Src,
which can regulate EGFR activation [43]. We propose
that by altering Cav1 composition in lipid rafts, Cav1
has decreased capacity for sequestering and negatively
regulating signaling complexes within caveolae. Indeed,
in the presence of Dsg2, the level of c-Src and EGFR is
similarly reduced in lipid raft fractions.
Upon ligand binding, activated receptor tyrosine
kinases such as EGFR undergo rapid endocytosis,
internalization and sorting to lysosomes for degradation
[58]. It is generally accepted that clathrin-mediated
endocytosis is the major pathway for internalization of
EGFR [59, 60]. Mounting evidence, however, supports
the role of membrane lipid rafts in modulating EGFR
level and activation. Treatment of HaCaT keratinocytes
with MβCD leads to accumulation of EGFR in large
clusters outside of the disrupted rafts resulting in enhanced
tyrosine kinase activity possibly due receptor clustering
or loss of inhibition [61]. It has been proposed that
autoactivation of EGFR may lead to internalization and
targeting for degradation through lipid rafts. Indeed, the
absence of Dsg2 has an effect both on the localization
of EGFR to lipid rafts (Figure 6) and the distribution of
Cav1 around the membrane (Figure 8); interrogating the
precise mechanism that Dsg2 influences EGFR trafficking
through lipid rafts will require additional study. In a
manner similar to manipulating lipid rafts with cholesterol
chelating agents, displacement of components from lipid
rafts results in activation of numerous signaling cascades
as well as alteration of differentiation markers such as
involucrin [62]. Transcriptional profiling of keratinocytes
after treatment with MβCD and identified over 3,000
differentially regulated genes [63]. It is evident that
altering lipid raft composition has a significant impact
on cellular communication and epithelial homeostasis.
Importantly, our findings provide a potential mechanism
for keratinocyte morphogenesis and malignant
transformation by Dsg2.
A number of targeted therapies directed against both
EGFR and c-Src are approved for the usage in a variety
of malignancies; no therapies currently exist for Cav1
[64]. EGFR-targeting small-molecule (gefitinib, erlotinib,
lapatinib, etc.) and antibody-based (cetuximab and
panitumumab) treatment modalities have been developed
to either block ligand-dependent receptor activation
or cytoplasmic kinase activity. EGFR inhibition-based
therapies are currently in use for a wide variety of solid
www.impactjournals.com/oncotarget

malignancies including non-small cell lung cancer, breast
cancer, and prostate cancer [65-67]. Though effective
in naïve disease, patients often experienced severe
side effects from the treatments and, depending on the
malignancy, progress to an EGFR-insensitive disease.
Additionally, a number of small-molecule tyrosine
kinase inhibitors (TKI) of c-Src have been shown to
have significant clinical effect, with the most well
characterized inhibitor being dasatanib. Dasatanib has
been used extensively as a second-line therapy in patients
with chronic myelogenous leukemia with the BCR-ABL
fusion protein, but, along with other c-Src-targeting TKIs,
has produced generally disappointing results in solid
malignancy clinical trials [68]. Combinatorial strategies
utilizing both EGFR and c-Src-directed inhibitors are
being explored in various solid tumors. Neither EGFR
nor c-Src-targeted therapies are approved for usage in
cutaneous SCCs, though clinical observations and trials
with cetuximab and gefitinib monotherapy have shown
efficacy in treating unresectable disease [69-71]. Given
the overexpression of EGFR and Dsg2 observed in SCCs,
and the relatively low expression of Dsg2 in the normal
adult interfollicular epidermis, a combinatorial therapy
of EGFR inhibitors with a Dsg2-directed modality may
prove useful in enhancing the effect of EGFR inhibition
while simultaneous limiting the adverse reactions to the
treatment [69].
Taken together, the data obtained here suggest that
Dsg2 may play a significant role in tumor development by
positively regulating EGFR level and signaling through a
c-Src and Cav1 dependent manner.

Materials and Methods
Antibodies
Antibodies used were: H145 Dsg2 (1:10,000), Cav1
(1:40,000), and GAPDH (1:3,000; Santa Cruz, Santa Cruz,
CA); Actin (1:100,000; Calbiochem, Billerica, MA);;
Flotillin 1, c-Src, P-c-Src Tyr416, P-c-Src Tyr527, EGFR,
P-EGFR Tyr1173, P-EGFR Tyr1045, P-EGFR Tyr845,
P-Erk1/2 (Thr202/Tyr204), P-AKT (Thr308), P-Stat3
(Tyr705) (1:1,000; Cell Signaling, Danvers, MA); 10D2
Dsg2 (1:2), 27B2 Dsg1 (1:100), 5H10 Dsg3 (1:100),
18D4 Dsg4 (1:100), desmocollin-2/3 7G6 (1:10,000),
20F6 desmoplakin (1:50), 14B11 plakophillin-1 (1:50),
8H6 plakophillin-2 (1:50), 19A5 plakophillin-3 (1:100),
11E4 plakoglobin (1:100), 4A2 E-cadherin (1:2,500), 6F9
β-catenin (1:1,000) [72]; Secondary antibodies: Alexa
Fluor-488 & -594 (1:400, Molecular Probes, Eugene, OR);
HRP (1:5,000; Jackson Labs, Bar Harbor, ME); IRDye
680 & 800(1:20,000; LI-COR Biosciences, Lincoln, NE);
Secondary antibodies for STED-imaging: Mega520conjugated anti-Rabbit (Sigma-Aldrich) and Star635P37550
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Proliferation assay

conjugated anti-Mouse (Abberior GmbH, Göttingen,
Germany).

Cellular proliferation rate was determined by
counting the number of cells after 6 days of proliferation.
Cells were seeded in triplicate at 5x103 cells per chamber
of 12-well culture plates (Corning, Corning, NY) in
complete DMEM with DMSO, Erlotinib (1μM), PP2
(5μM) or the combination treatment. Six days post
seeding, cells were trypsinized (0.25% Trypsin-EDTA)
and counted.

Molecular constructs
Short hairpin RNAs (shRNA) targeting human Dsg2
were generated by the synthesis of oligonucleotides per the
pSuper retro puro user manual (Oligoengine, Seattle, WA)
using the gene specific sequences: (‘5-GAT CCC CGA
GAG GAT CTG TCC AAG AAT TCA AGA GAT TCT
TGG ACA GAT CCT CTC TTT TT-3’ and ‘5-AGC TTA
AAA AGA GAG GAT CTG TCC AAG AAT CTC TTG
AAT TCT TGG ACA GAT CCT CTC GGG-3’). Control
shRNA targeting Green Fluorescent Protein was generated
as previously described [73]. Oligos were annealed and
ligated to pSuper-retro-puro. Retroviral particles were
generated and stable HaCaT (immortal keratinocytes)
and A431 (squamous carcinoma) cell lines were selected
in medium containing 2 μg/mL puromycin. The Dsg2
cDNA was subcloned upstream of GFP in pEGFP-N1
(Clontech, Mountainview, CA). The GFP and Dsg2-GFP
cDNAs were subcloned into the retroviral expression
vector LZRS-ms-neo and transfected into Phoenix cells.
Retroviral particles were generated and stable A431 and
HT1080 (fibrosarcoma) cells were selected in G418 (50
μg/ml) as previously described [73]. During the course
of this study we made several interesting observations.
First, it was difficult to maintain the Dsg2 knock-down
phenotype in A431 SCC cells as the cultures would select
for Dsg2-expressing cells over time, even in the presence
of selection medium. Second, the Dsg2-GFP construct
used to overexpress Dsg2 in the A431s did not adequately
overexpress the protein in HaCaTs. These cells would
often slightly downregulate endogenous Dsg2 and have a
similar level of total Dsg2 to that of the control cells.

Transwell migration assay
Cell migration was performed with 5x103 HT1080
cells or 5x104 A431 cells plated in the top chamber of the
Transwell insert on an uncoated membrane (8 μm pores
for A431 and 2 μm pores for HT1080; Corning). Cells
were seeded in the upper chamber in serum-free DMEM
with the same concentration of inhibitors utilized for the
proliferation assay; 10% FBS-containing DMEM was
the chemoattractant in the lower chamber. Cells were
allowed to migrate for 18-24 h then rinsed in PBS,fixed
in paraformaldehyde and stained with 0.5% crystal violet
in 50% methanol. Unmigrated cells in the upper chambers
were removed with a cotton swab, and migrated cells in
the lower chambers were imaged in 5 random fields using
an inverted microscope (EVOS, Life Technologies, Grand
Island, NY).

Isolation of lipid raft fractions
Cells were lysed with TNE buffer (25 mM TrisHCl, pH 7.5, 150 mM NaCl, 5 mM EDTA) containing
1% TX-100 and supplemented with PMSF (1 mM),
protease inhibitors (Roche Diagnostics, Indianapolis,
IN), and phosphatase inhibitors (Sigma, St. Louis, MO)
and homogenized with a Dounce Homogenizer. Equal
volume of 90% sucrose and cell lysate were mixed and
overlayed with equal volume of 35% sucrose followed by
5% sucrose all in TNE buffer. Samples were centrifuged
at 4°C for 18-20 h at 38,000 rpm using an SW41Ti rotor
(Beckman Coulter, Brea, CA). From top, twelve fractions
were collected and prepared for Western blotting analysis.

Cell culture and drug treatment
HaCaT, A431, and HT1080 cells were maintained
in DMEM complete medium containing 10% fetal bovine
serum (FBS; Fisher, Waltham, MA) and 1X penicillin/
streptomycin (Fisher) as previously described [74, 75].
Cells were incubated in serum-free DMEM for 1 h prior to
treatment with EGF (10 ng/mL; Invitrogen, Carlsbad, CA)
for the indicated time (0-60 min). In some experiments,
cells were pre treated with PD098059 (50 µM; BioMol
Research, Plymouth Meeting, PA), Wortmannin (100
nM; BioMol Research), or PP2 (10 µM; Millipore Corp.,
Billerica, MA) for 1 h. prior to EGF stimulation. To disrupt
lipid rafts, cells were treated with MβCD (1 %) for 1 h.
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Cell immunoblotting and immunohistochemistry
Cells were lysed with lysis buffer (50 mM TrisHCl pH 7.5, 150 mM NaCl, 5 mM EDTA, and 1% TX100) supplemented with PMSF, protease and phosphatase
inhibitors and heated to 95°C for 10 m in Laemmli
buffer. Proteins were resolved over SDS-PAGE gel (BioRad Labs, Hercules, CA). Membranes were blocked in
Odyssey blocking buffer (LI-COR, Lincohn, NE) and
incubated in primary antibody overnight at 4°C, followed
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